251 related articles for article (PubMed ID: 36986819)
1. The Hedgehog Pathway as a Therapeutic Target in Chronic Myeloid Leukemia.
Wu A; Turner KA; Woolfson A; Jiang X
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986819
[TBL] [Abstract][Full Text] [Related]
2. Hedgehog pathway activation in chronic myeloid leukemia.
Jagani Z; Dorsch M; Warmuth M
Cell Cycle; 2010 Sep; 9(17):3449-56. PubMed ID: 20928937
[TBL] [Abstract][Full Text] [Related]
3. Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia.
Jamieson C; Martinelli G; Papayannidis C; Cortes JE
Blood Cancer Discov; 2020 Sep; 1(2):134-145. PubMed ID: 34661144
[TBL] [Abstract][Full Text] [Related]
4. Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+ CML stem/progenitor cells.
Babashah S; Sadeghizadeh M; Hajifathali A; Tavirani MR; Zomorod MS; Ghadiani M; Soleimani M
Int J Cancer; 2013 Aug; 133(3):579-89. PubMed ID: 23341351
[TBL] [Abstract][Full Text] [Related]
5. Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status.
Cea M; Cagnetta A; Cirmena G; Garuti A; Rocco I; Palermo C; Pierri I; Reverberi D; Nencioni A; Ballestrero A; Gobbi M; Carella AM; Patrone F
Leuk Lymphoma; 2013 Feb; 54(2):342-52. PubMed ID: 22762548
[TBL] [Abstract][Full Text] [Related]
6. Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia.
Irvine DA; Zhang B; Kinstrie R; Tarafdar A; Morrison H; Campbell VL; Moka HA; Ho Y; Nixon C; Manley PW; Wheadon H; Goodlad JR; Holyoake TL; Bhatia R; Copland M
Sci Rep; 2016 May; 6():25476. PubMed ID: 27157927
[TBL] [Abstract][Full Text] [Related]
7. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
8. Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment.
Terao T; Minami Y
Cells; 2019 Apr; 8(4):. PubMed ID: 30987263
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
Brechbiel J; Miller-Moslin K; Adjei AA
Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
[TBL] [Abstract][Full Text] [Related]
10. Hedgehog/GLI signaling in hematopoietic development and acute myeloid leukemia-From bench to bedside.
Tesanovic S; Krenn PW; Aberger F
Front Cell Dev Biol; 2022; 10():944760. PubMed ID: 35990601
[TBL] [Abstract][Full Text] [Related]
11. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia.
Zhao C; Chen A; Jamieson CH; Fereshteh M; Abrahamsson A; Blum J; Kwon HY; Kim J; Chute JP; Rizzieri D; Munchhof M; VanArsdale T; Beachy PA; Reya T
Nature; 2009 Apr; 458(7239):776-9. PubMed ID: 19169242
[TBL] [Abstract][Full Text] [Related]
12. Understanding the Hedgehog Signaling Pathway in Acute Myeloid Leukemia Stem Cells: A Necessary Step toward a Cure.
Lainez-González D; Serrano-López J; Alonso-Domínguez JM
Biology (Basel); 2021 Mar; 10(4):. PubMed ID: 33804919
[TBL] [Abstract][Full Text] [Related]
13. Casein Kinase 1D Encodes a Novel Drug Target in Hedgehog-GLI-Driven Cancers and Tumor-Initiating Cells Resistant to SMO Inhibition.
Peer E; Aichberger SK; Vilotic F; Gruber W; Parigger T; Grund-Gröschke S; Elmer DP; Rathje F; Ramspacher A; Zaja M; Michel S; Hamm S; Aberger F
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439381
[TBL] [Abstract][Full Text] [Related]
14. The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis.
Mar BG; Amakye D; Aifantis I; Buonamici S
Leukemia; 2011 Nov; 25(11):1665-73. PubMed ID: 21660044
[TBL] [Abstract][Full Text] [Related]
15. Nonhematopoietic cells represent a more rational target of in vivo hedgehog signaling affecting normal or acute myeloid leukemia progenitors.
Boyd AL; Salci KR; Shapovalova Z; McIntyre BA; Bhatia M
Exp Hematol; 2013 Oct; 41(10):858-869.e4. PubMed ID: 23747997
[TBL] [Abstract][Full Text] [Related]
16. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
Li QR; Zhao H; Zhang XS; Lang H; Yu K
Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
[TBL] [Abstract][Full Text] [Related]
17. Activation of the Hedgehog pathway in chronic myelogeneous leukemia patients.
Long B; Zhu H; Zhu C; Liu T; Meng W
J Exp Clin Cancer Res; 2011 Jan; 30(1):8. PubMed ID: 21235817
[TBL] [Abstract][Full Text] [Related]
18. Hedgehog pathway as a drug target: Smoothened inhibitors in development.
Lin TL; Matsui W
Onco Targets Ther; 2012; 5():47-58. PubMed ID: 22500124
[TBL] [Abstract][Full Text] [Related]
19. Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia.
Shallis RM; Bewersdorf JP; Boddu PC; Zeidan AM
Expert Rev Anticancer Ther; 2019 Aug; 19(8):717-729. PubMed ID: 31422721
[No Abstract] [Full Text] [Related]
20. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists.
Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y
Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
